^
Association details:
| Biomarker: | NUP214-ABL1 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1602 Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present
Published date:
11/02/2023
Excerpt:
Asciminib also demonstrated efficacy in pre-clinical mouse models of NUP214::ABL1 ALL...Asciminib treatment significantly increased survival outcomes compared with control mice (84 vs 46d, p=0.01) by a time comparable to that of dasatinib treatment (93 vs 46d, p=0.0046).
